PrimeVax Immuno-Oncology
PrimeVax is a clinical stage immuno-oncology company developing novel therapies for cancer. They are pioneering the use of the Dengue Virus as an oncolytic virotherapy to address late-stage failed treatment markets, leveraging the virus's immuno-stimulatory properties to prime the human body to fight cancer.
Industries
Nr. of Employees
small (1-50)
PrimeVax Immuno-Oncology
Patents
Compositions and methods for combination therapy with dengue virus and dendritic cells
US-10159727-B2
View DetailsCompositions and methods for combination therapy with dengue virus and dendritic cells
US-9849167-B2
View DetailsCompositions and methods for combination therapy with dengue virus and dendritic cells
US-9730989-B2
View Details
Compositions and methods for combination therapy with dengue virus and dendritic cells
US-10159727-B2
View DetailsCompositions and methods for combination therapy with dengue virus and dendritic cells
US-9849167-B2
View DetailsCompositions and methods for combination therapy with dengue virus and dendritic cells
US-9730989-B2
View DetailsProducts
Live attenuated dengue virus‑based oncolytic therapy (attenuated DENV‑1 strain)
A live, naturally attenuated dengue virus strain repurposed as an oncolytic virotherapy intended to induce systemic immune activation and direct tumor cell killing in late‑stage cancers.
PV001-DV
PV001-DV is a live, attenuated strain of Dengue Virus developed as a first-in-class oncolytic virotherapy for late-stage cancers, demonstrating a strong anti-cancer immune response and high safety profile.
Live attenuated dengue virus‑based oncolytic therapy (attenuated DENV‑1 strain)
A live, naturally attenuated dengue virus strain repurposed as an oncolytic virotherapy intended to induce systemic immune activation and direct tumor cell killing in late‑stage cancers.
PV001-DV
PV001-DV is a live, attenuated strain of Dengue Virus developed as a first-in-class oncolytic virotherapy for late-stage cancers, demonstrating a strong anti-cancer immune response and high safety profile.
Services
Partnered preclinical studies and IND‑enabling research to generate safety, mechanism, and efficacy data for oncology candidates.
Execution of Phase 1a safety studies and planned Phase 1b/2 dose‑finding studies in oncology patients, including design for PD‑1 refractory melanoma cohorts.
Scale‑up and production of clinical drug product under cGMP through partner manufacturing and licensing agreements to support clinical programs.
Partnered preclinical studies and IND‑enabling research to generate safety, mechanism, and efficacy data for oncology candidates.
Execution of Phase 1a safety studies and planned Phase 1b/2 dose‑finding studies in oncology patients, including design for PD‑1 refractory melanoma cohorts.
Scale‑up and production of clinical drug product under cGMP through partner manufacturing and licensing agreements to support clinical programs.
Expertise Areas
- Oncolytic virotherapy development
- Early‑phase clinical trial management
- Regulatory submissions and master file management (FDA IND)
- cGMP clinical drug product manufacturing and scale‑up
Key Technologies
- Live attenuated virus‑based oncolytic therapy
- Experimental human infection (human challenge) models
- Single‑cell RNA sequencing
- PBMC immunophenotyping and immune biomarker assays